Calorie Intake And Glp-1 And Statin Therapy For Patients With Liver Disease

In this review we discuss the rationale, available evidence and gaps of incretin-based therapies on MASLD/MASH, with a focus on GLP-1 and glucagon receptor dual agonists.

ny effect of GLP1 agonists on MASH is therefore likely to be indirect and may be related to a reduction in calorie intake, body weight and insulin resistance, all of which lead to reduced liver lipid accumulation and hepatic inflammation (Fig. 1).

Emerging data suggest that glucagonlike peptide1 receptor agonists (GLP1 RAs), originally developed for glycemic control and weight management, may have direct hepatic benefits even in patients who are not visibly obese or overtly diabetic.

This particular example perfectly highlights why Calorie Intake And Glp-1 And Statin Therapy For Patients With Liver Disease is so captivating.

GLP-1 medications, such as semaglutide and tirzepatide, were originally designed for diabetes, but their impact on weight, inflammation, and metabolic health has fundamentally changed how we approach liver disease.

Effective treatment of these conditions is essential to reduce the liver disease burden, with promising approaches including treating cardiometabolic risk factors and excessive alcohol intake.

Objective: To investigate the effect of GLP-1 agonists, including dual and triple agonists, in patients with metabolic-associated liver steatosis and steatohepatitis, while exploring their effect on patients with and without type 2 diabetes.